| Title |
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
|
|---|---|
| Published in |
OncoTargets and therapy, March 2017
|
| DOI | 10.2147/ott.s98689 |
| Pubmed ID | |
| Authors |
Maliha Khan, Jamie L Gibbons, Alessandra Ferrajoli |
| Abstract |
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the adult population. Current efforts are focused on better understanding the intricate pathophysiology of the disease to develop successful targeted therapies. Ibrutinib is emerging as an important agent in this new age of targeted treatment for CLL. As a Bruton's tyrosine kinase inhibitor, it blocks the signaling pathway that malignant B-lymphocytes need for growth and maturation. Ibrutinib's role in therapy was further expanded recently when the US Food and Drug Administration approved its use in both frontline and salvage treatment for patients with CLL. This review assesses the effectiveness of ibrutinib in the frontline setting, its efficacy in various types of patients with CLL, and its safety and tolerability. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 23% |
| Student > Bachelor | 3 | 14% |
| Researcher | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Librarian | 1 | 5% |
| Other | 4 | 18% |
| Unknown | 5 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Chemical Engineering | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 6 | 27% |